申请人:Horuriku Seiyaku Co., Ltd.
公开号:US05547962A1
公开(公告)日:1996-08-20
A 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative represented by the general formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a lower alkyl group; R.sup.2 is a hydrogen atom, a lower alkyl group, a lower alkanoyl group, a halogenated lower alkanoyl group or a residue of carboxylic acid ester; R.sup.3 is a hydrogen atom or a lower alkyl group; R.sup.4, R.sup.5 or R.sup.6 are each independently a hydrogen atom or a lower alkyl group; or two of R.sup.4, R.sup.5 and R.sup.6 may be taken together to form a --(CH.sub.2).sub.n -group wherein n is 1 or 2, a stereoisomer thereof, or a pharmacologically acceptable salt thereof, the process for preparing these compounds, a pharmaceutical composition comprising an effective amount of these compounds and methods for the treatment of infectious diseases through the administration to patients of an effective amount of these compounds, and intermediates of these compounds are disclosed. These compounds are effective as antibacterial agents.
本发明涉及一种5-氨基-8-甲基-7-吡咯烷基喹啉-3-羧酸衍生物,其通式表示为:##STR1##
其中R1为氢原子或低碳基;R2为氢原子、低碳基、低碳酰基、卤代低碳酰基或羧酸酯残基;R3为氢原子或低碳基;R4、R5或R6各自独立地为氢原子或低碳基;或者R4、R5和R6中的两个可取代为--(CH2)n-基团,其中n为1或2,其立体异构体或其药理学上可接受的盐,以及制备这些化合物的方法,包括含有这些化合物的有效量的制药组合物和通过向患者施用这些化合物的有效量来治疗传染病的方法,以及这些化合物的中间体。这些化合物作为抗菌剂具有良好的效果。